-
Mashup Score: 38AL amyloidosis response: a move in the “light” direction - 10 day(s) ago
As redemonstrated by Bomsztyk et al1 in this issue of Blood, top-down mass spectrometry (MS) of blood has been transformative for diagnosing and monitoring
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 35AL amyloidosis response: a move in the “light” direction - 13 day(s) ago
As redemonstrated by Bomsztyk et al1 in this issue of Blood, top-down mass spectrometry (MS) of blood has been transformative for diagnosing and monitoring
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
👍🏽editorial by @ADispenzieri on FLC-Mass Spect in AL amyloidosis by @awechalekar's group. I love the way Dr. Dispenzieri masterfully distills the key findings in one figure! A must-read and should be a benchmark for how to write an excellent commentary. https://t.co/oEWRnHlnOq https://t.co/Ai6Jr0BNTC https://t.co/iXGuMV4DbP
-
-
Mashup Score: 2First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy - PubMed - 20 day(s) ago
Although Dara-VCD (daratumumab-bortezomib-cyclophosphamide-dexamethasone) has revolutionized the treatment of newly diagnosed Amyloid Light chain (AL) amyloidosis, patients with stage IIIb disease were excluded in the pivotal trial. We performed a multicentre retrospective cohort study to investigat …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 38
Not available.
Source: haematologica.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4
Johnson & Johnson Pharmaceutical Research and Development, and Millennium Pharmaceuticals.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet-
@RahulBanerjeeMD @JanakiramMurali @HiraSMian @GKaurMD @JanssenUS @VincentRK Agree that RCT or once vs twice weekly V will never happen at this point (and I wouldn’t enroll my patient into it even if it did). However, we do have an RCT of IV vs sq Velcade, which likely led to widespread adoption of sq early on. (https://t.co/iVUzQ2ZlHW)
-
-
Mashup Score: 101Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma - 2 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Partners & KOLsTweet-
Our paper on natural history, mode of progression, and discordance between risk-stratification models in ~100 consecutive patients with Smoldering Myeloma diagnosed since 2014 @columbiacancer (led by @Slade_Mellgard)- Now out in @Hemasphere_EHA! #mmsm 🧵 https://t.co/nz5RrtjWS6 https://t.co/VvHYMgFxRI
-
-
Mashup Score: 3Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon? - 2 month(s) ago
The phenomenon of stage migration in cancers leads to apparent survival improvement in both lower and higher stages. This is due to an upward migration of patients with adverse biology from lower to higher stages, as well as newcomers in higher stages who are not as clinically advanced as the original cohort in that stage. This epidemiological paradox is called ‘Will Rogers phenomenon’ after the comedian Will Rogers, who, during the large-scale geographic migration of 1930s, had putatively said, ‘When the Okies left Oklahoma and moved to California, they raised the average intelligence level in both states’ [1].
Source: www.ejcancer.comCategories: General Medicine News, Partners & KOLsTweet-
In 2014, the diagnostic criteria of Myeloma was modified to include biomarkers (SLiM) in the absence of CRAB, leading to a potential Will Roger's phenomenon. (https://t.co/KysFrX66jt) We hypothesized that a modern cohort of pts with SMM will have a substantially lower risk of… https://t.co/JTx8BBYfhc
-
-
Mashup Score: 96Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma - 2 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Partners & KOLsTweet-
Our paper on natural history, mode of progression, and discordance between risk-stratification models in ~100 consecutive patients with Smoldering Myeloma diagnosed since 2014 @columbiacancer (led by @Slade_Mellgard)- Now out in @Hemasphere_EHA! #mmsm 🧵 https://t.co/nz5RrtjWS6 https://t.co/VvHYMgFxRI
-
-
Mashup Score: 35The Curbsiders Internal Medicine Podcast: #427 Kittleson Rules Amyloidosis on Apple Podcasts - 2 month(s) ago
Show The Curbsiders Internal Medicine Podcast, Ep #427 Kittleson Rules Amyloidosis – Feb 19, 2024
Source: podcasts.apple.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time - PubMed - 2 month(s) ago
Purpose Autologous stem-cell transplantation (ASCT) has been used in patients with immunoglobulin light chain (AL) amyloidosis for more than two decades. Early experience raised concerns regarding safety with high early-mortality rates. Patients and Methods We report 20 years of experience with ASCT …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
👍🏽editorial by @ADispenzieri on FLC-Mass Spect in AL amyloidosis by @awechalekar's group. I love the way Dr. Dispenzieri masterfully distills the key findings in one figure! A must-read and should be a benchmark for how to write an excellent commentary. https://t.co/oEWRnHlnOq https://t.co/Ai6Jr0BNTC https://t.co/iXGuMV4DbP